• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.监管决策辅助工具的真实世界证据:一个用于指导临床开发和监管策略的互动工具。
Adv Ther. 2022 Oct;39(10):4772-4778. doi: 10.1007/s12325-022-02257-4. Epub 2022 Aug 16.
2
Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.在线工具合成比较有效性研究的真实世界证据,以加强处方决策。
J Manag Care Spec Pharm. 2021 Jan;27(1):95-104. doi: 10.18553/jmcp.2021.27.1.095.
3
Trial designs using real-world data: The changing landscape of the regulatory approval process.使用真实世界数据的试验设计:监管审批流程的不断变化态势。
Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1201-1212. doi: 10.1002/pds.4932. Epub 2019 Dec 10.
4
Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World.用于监管决策的真实世界证据:来自世界各地的指南。
Clin Ther. 2022 Mar;44(3):420-437. doi: 10.1016/j.clinthera.2022.01.012. Epub 2022 Feb 15.
5
Real-world evidence to support regulatory submissions: A landscape review and assessment of use cases.支持监管提交的真实世界证据:案例分析及应用评估。
Clin Transl Sci. 2024 Aug;17(8):e13903. doi: 10.1111/cts.13903.
6
Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.两种用于监管决策的真实世界数据和真实世界证据评估方法的比较。
Clin Transl Sci. 2024 Jan;17(1):e13702. doi: 10.1111/cts.13702.
7
A Comprehensive Framework for Evaluating the Value Created by Real-World Evidence for Diverse Stakeholders: The Case for Coordinated Registry Networks.用于评估真实世界证据为不同利益相关者创造的价值的综合框架:以协作登记网络为例。
Ther Innov Regul Sci. 2024 Nov;58(6):1042-1052. doi: 10.1007/s43441-024-00680-z. Epub 2024 Jul 25.
8
RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design.真实世界证据框架:一种支持真实世界证据研究设计的交互式可视化工具。
Drugs Real World Outcomes. 2019 Dec;6(4):193-203. doi: 10.1007/s40801-019-00167-6.
9
[The application of real-world evidence in drug regulatory decision-making].[真实世界证据在药品监管决策中的应用]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024 Feb;67(2):149-154. doi: 10.1007/s00103-023-03830-0. Epub 2024 Jan 12.
10
Contribution of Real-World Evidence in European Medicines Agency's Regulatory Decision Making.真实世界证据在欧洲药品管理局监管决策中的贡献。
Clin Pharmacol Ther. 2023 Jan;113(1):135-151. doi: 10.1002/cpt.2766. Epub 2022 Nov 4.

引用本文的文献

1
Consensus Statements on Precision Oncology in the China Greater Bay Area.精准肿瘤学在粤港澳大湾区的共识声明。
JCO Precis Oncol. 2023 Jun;7:e2200649. doi: 10.1200/PO.22.00649.

本文引用的文献

1
When Context Is Hard to Come By: External Comparators and How to Use Them.当难以获得背景信息时:外部比较器及其使用方法。
Ther Innov Regul Sci. 2019 Nov 5:2168479019878672. doi: 10.1177/2168479019878672.

监管决策辅助工具的真实世界证据:一个用于指导临床开发和监管策略的互动工具。

Real World-Evidence for Regulatory Use Decision Aid: An Interactive Tool To Inform Clinical Development and Regulatory Strategies.

机构信息

WWHEOR, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA.

Global Regulatory Strategy and Policy, Bristol Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA.

出版信息

Adv Ther. 2022 Oct;39(10):4772-4778. doi: 10.1007/s12325-022-02257-4. Epub 2022 Aug 16.

DOI:10.1007/s12325-022-02257-4
PMID:35972721
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9379219/
Abstract

Real-world evidence (RWE) is increasingly used to complement clinical trial data for regulatory decision-making and in certain cases utilized to establish the clinical effectiveness of a therapy. However, the use of RWE is not applicable for all regulatory submissions, and it can be challenging to identify appropriate use cases. An interactive tool was developed ("Decision Aid," https://sn.pub/TpDjZx ) to assist researchers, industry, and other stakeholders in identifying regulatory situations that can benefit from leveraging RWE by organizing precedent cases based on a given regulatory objective (new product approval, labeling expansion for new indication or additional clinical data, post-marketing requirement) and type of RWE study design (external control, observational study, pragmatic trial). Key success factors ensuring fit-for-purpose data and rigorous methods (e.g., clear endpoints, minimizing bias, data completeness) are also described. The tool allows the user to navigate through the precedent cases by selecting certain regulatory objectives and/or study designs. The Decision Aid supports regulatory activities in the RWE space and encourages further use of RWE in regulatory decision-making.

摘要

真实世界证据(RWE)越来越多地被用于补充临床试验数据以支持监管决策,并且在某些情况下,还被用于确定某种疗法的临床疗效。然而,RWE 的应用并非适用于所有监管提交,并且确定合适的应用场景可能具有挑战性。我们开发了一个交互式工具(“决策辅助工具”,https://sn.pub/TpDjZx),旨在通过基于特定监管目标(新产品批准、新适应症或额外临床数据的标签扩展、上市后要求)和 RWE 研究设计类型(外部对照、观察性研究、实用试验)组织先例案例,来帮助研究人员、行业和其他利益相关者识别可以从利用 RWE 中受益的监管情况,从而协助研究人员、行业和其他利益相关者识别可以从利用 RWE 中受益的监管情况。该工具还描述了确保适用数据和严格方法(例如,明确终点、最小化偏倚、数据完整性)的关键成功因素。该工具允许用户通过选择特定的监管目标和/或研究设计来浏览先例案例。该决策辅助工具支持 RWE 领域的监管活动,并鼓励在监管决策中进一步使用 RWE。